Toll-like receptor 4 gene Asp299Gly polymorphism in myocardial infarction: A meta-analysis of 15,148 subjects

Human Immunology

Volumn 75, Issue 2, 2014, Pages 163-169

  Yin, Yan Wei ^a   Sun, Qian Qian ^b   Hu, Ai Min ^a   Liu, Hong Li ^a   Wang, Qi ^a   Zhang, Bei Bei ^c  

^a AIR FORCE GENERAL HOSPITAL   (China)

^b Jinsong Sanatorium of Beijing Air Force   (China)

^c General Hospital of PLA Chengdu Military Area Command   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; GLYCINE; TOLL LIKE RECEPTOR 4; TLR4 PROTEIN, HUMAN;

ARTICLE; DNA POLYMORPHISM; EMBASE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY;

GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; TOLL-LIKE RECEPTOR 4;

EID: 84892368342     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.11.005     Document Type: Article

References (40)

1. American Heart Association. Available at: 2012 [accessed 10.11.12]. http://www.heart.org/HEARTORG/.
2. British Heart Foundation. Available at: 2012 [accessed 10.11.12]. http://www.bhf.org.uk/.
3. Bowron A., Scott J., Stansbie D. The influence of genetic and environmental factors on plasma homocysteine concentrations in a population at high risk for coronary artery disease. Ann Clin Biochem 2005, 42:459-462.
4. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001, 88:10K-15K.
5. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138:S419-S420.
6. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
7. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
8. Binder C.J., Chang M.K., Shaw P.X., Miller Y.I., Hartvigsen K., Dewan A., et al. Innate and acquired immunity in atherogenesis. Nat Med 2002, 8:1218-1226.
9. Hansson G.K., Libby P., Schonbeck U., Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002, 91:281-291.
10. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680.
11. Schröder N.W., Schumann R.R. Single nucleotide polymorphisms of toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005, 5:156-164.
12. Candore G., Colonna-Romano G., Balistreri C.R., Di Carlo D., Grimaldi M.P., Listì F., et al. Biology of longevity: role of the innate immune system. Rejuvenation Res 2006, 9:143-148.
13. Ozturk A., Vieira A.R. TLR4 as a risk factor for periodontal disease: a reappraisal. J Clin Periodontol 2009, 36:279-286.
14. Xu X.H., Shah P.K., Faure E., Equils O., Thomas L., Fishbein M.C., et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001, 104:3103-3108.
15. Michelsen K.S., Doherty T.M., Shah P.K., Arditi M. TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol 2004, 173:5901-5907.
16. Pasterkamp G., Van Keulen J.K., De Kleijn D.P. Role of toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest 2004, 34:328-334.
17. Nebel A., Flachsbart F., Schäfer A., Nothnagel M., Nikolaus S., Mokhtari N.E., et al. Role of the toll-like receptor 4 polymorphism Asp299Gly in longevity and myocardial infarction in German men. Mech Ageing Dev 2007, 128:409-411.
18. Buraczynska M., Baranowicz-Gaszczyk I., Tarach J., Ksiazek A. Toll-like receptor 4 gene polymorphism and early onset of diabetic retinopathy in patients with type 2 diabetes. Hum Immunol 2009, 70:121-124.
19. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000, 25:187-191.
20. Rallabhandi P., Bell J., Boukhvalova M.S., Medvedev A., Lorenz E., Arditi M., et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol 2006, 177:322-332.
21. Kinane D.F., Shiba H., Stathopoulou P.G., Zhao H., Lappin D.F., Singh A., et al. Gingival epithelial cells heterozygous for toll-like receptor 4 polymorphisms Asp299Gly and Thr399ile are hypo-responsive to Porphyromonas gingivalis. Genes Immun 2006, 7:190-200.
22. Montes A.H., Asensi V., Alvarez V., Valle E., Ocaña M.G., Meana A., et al. The toll-like receptor (Asp299Gly) polymorphism is a risk factor for gram-negative and haematogenous osteomyelitis. Clin Exp Immunol 2006, 143:404-413.
23. Boekholdt S.M., Agema W.R., Peters R.J., Zwinderman A.H., van der Wall E.E., Reitsma P.H., et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003, 107:2416-2421.
24. Edfeldt K., Bennet A.M., Eriksson P., Frostegård J., Wiman B., Hamsten A., et al. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 2004 Aug, 25(16):1447-1453.
25. Balistreri C.R., Candore G., Colonna-Romano G., Lio D., Caruso M., Hoffmann E., et al. Role of toll-like receptor 4 in acute myocardial infarction and longevity. JAMA 2004, 292:2339-2340.
26. Zee R.Y., Hegener H.H., Gould J., Ridker P.M. Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis. Stroke 2005, 36:154-157.
27. Koch W., Hoppmann P., Pfeufer A., Schömig A., Kastrati A. Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. Eur Heart J 2006, 27:2524-2529.
28. Džumhur A., Zibar L., Wagner J., Simundić T., Dembić Z., Barbić J. Association studies of gene polymorphisms in toll-like receptors 2 and 4 in Croatian patients with acute myocardial infarction. Scand J Immunol 2012, 75:517-523.
29. Holloway J.W., Yang I.A., Ye S. Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet Genomics 2005, 15:15-21.
30. Beijk M.A., Boekholdt S.M., Rittersma S.Z., Pons D., Zwinderman A.H., Doevendans P.A., et al. Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention. Pharmacogenet Genomics 2010, 20:544-552.
31. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. PRISMA group.
32. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Health Research Institute. [accessed 20.10.11]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
33. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
34. Berkey C.S., Hoaglin D.C., Mosteller F., Colditz G.A. A random-effects regression model for meta-analysis. Stat Med 1995, 14:395-411.
35. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer 1959, 22:719-748.
36. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
37. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
38. Zhang K., Zhang L., Zhou B., Wang Y., Song Y., Rao L., et al. Lack of association between TLR4 Asp299Gly polymorphism and atherosclerosis: evidence from meta-analysis. Thromb Res 2012, 130:e203-e208.
39. Zintzaras E., Lau J. Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 2008, 61:634.
40. International HapMap Project. Available at: 2013 [accessed 15.08.13]. http://hapmap.ncbi.nlm.nih.gov.